Breaking World Pharma News
GSK and Vir Biotechnology announce Joint Procurement Agreement with European Commission for COVID-19 treatment, sotrovimab
GlaxoSmithKline plc and Vir Biotechnology, Inc. announced they have signed a Joint Procurement Agreement with the European Commission to supply up to 220,000 doses of sotrovimab, an investigational single dose SARS-CoV-2 monoclonal antibody for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with COVID-19 who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19. FDA approves first interchangeable biosimilar insulin product for treatment of diabetes
The U.S. Food and Drug Administration approved the first interchangeable biosimilar insulin product, indicated to improve glycemic control in adults and pediatric patients with Type 1 diabetes mellitus and in adults with Type 2 diabetes mellitus. Semglee (insulin glargine-yfgn) is both biosimilar to, and interchangeable with (can be substituted for), its reference product Lantus (insulin glargine), a long-acting insulin analog. Vaxzevria and mRNA COVID-19 vaccines showed similar and favourable safety profiles in a population-based cohort study of over a million people
In a large real-world study, data published as a pre-print on The Lancet server from over one million individuals assessed the incidence rates of blood clotting disorders of thromboembolism and thrombocytopenia, including the very rare thrombosis with thrombocytopenia (TTS) following vaccination with an mRNA vaccine or Vaxzevria, and compared them with expected rates in a general population and in people with COVID-19. Pfizer and BioNTech to provide U.S. government with an additional 200 million doses of COVID-19 vaccine
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. government has purchased an additional 200 million doses of the Pfizer-BioNTech COVID-19 Vaccine. These doses are expected to be delivered from October 2021 through April 2022. This brings the total number of doses to be supplied by the companies to the U.S. government under its existing supply agreement to 500 million. AstraZeneca and Regeneron to research, develop and commercialise new small molecule medicines for obesity
AstraZeneca has entered into a collaboration with Regeneron to research, develop and commercialise small molecule compounds directed against the GPR75 target with the potential to treat obesity and related co-morbidities. Advantages of intranasal vaccination against SARS-CoV-2
Japan becomes first country to approve Ronapreve (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Ronapreve™ (casirivimab and imdevimab), for the treatment of patients with mild to moderate COVID-19 via intravenous infusion. Antibiotics may help to treat melanoma
Pfizer and BioNTech announce collaboration with Biovac to manufacture and distribute COVID-19 vaccine doses within Africa
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the signing of a letter of intent with The Biovac Institute (Pty) Ltd, known as "Biovac," a Cape Town-based, South African biopharmaceutical company, to manufacture the Pfizer-BioNTech COVID-19 Vaccine for distribution within the African Union. More Pharma News ...
Business & Industry
- GSK and Vir Biotechnology announce Joint Procurement Agreement with European Commission for COVID-19 treatment, sotrovimab
- Vaxzevria and mRNA COVID-19 vaccines showed similar and favourable safety profiles in a population-based cohort study of over a million people
- Pfizer and BioNTech to provide U.S. government with an additional 200 million doses of COVID-19 vaccine
- AstraZeneca and Regeneron to research, develop and commercialise new small molecule medicines for obesity
- Japan becomes first country to approve Ronapreve (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19
Research & Development
- Thinking impaired in 60% of COVID-19 survivors
- Advantages of intranasal vaccination against SARS-CoV-2
- Antibiotics may help to treat melanoma
- Take your best shot: Which SARS-CoV-2 vaccine should I get, if any?
- Study shows why second dose of COVID-19 vaccine shouldn't be skipped
- Are silver nanoparticles a silver bullet against microbes?
- One shot of the Sputnik V vaccine triggers strong antibody responses
Conferences & Events
- Novartis, Bayer and Boehringer Ingelheim to showcase their commitment to a reimagined pharma industry
- Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
- CPhI Worldwide to return in 2021
- Reuters Events' Cell & Gene Therapy USA
- Total health: Build a better healthcare system
- Don't fall for the 'next best action' trap
- Locking down shape-shifting spike protein aids development of COVID-19 vaccine
Regulatory Affairs
- FDA approves first interchangeable biosimilar insulin product for treatment of diabetes
- FDA approves first oral blood thinning medication for children
- FDA grants accelerated approval for Alzheimer's drug
- FDA approves new drug treatment for chronic weight management, first since 2014
- FDA authorizes additional monoclonal antibody for treatment of COVID-19